Avandia, Rosiglitazone News

Makers of new diabetes drugs, led by Bristol-Myers Squibb Co., Novartis AG and AstraZeneca Plc, should be required to research long-term heart risks before bringing their products to market, a U.S. panel said ...

Diabetes drug makers will soon face tougher safety standards that could cost manufacturers millions.

Diabetes drug makers are starting to face a regulatory conumdrum heart drug makers began to face last year.

July 3, 2008 -- Drug companies should be required to conduct stricter safety tests before marketing new diabetes drugs, expert advisors tell the FDA.

Diabetes Drugs-Heart Risks Longer testing suggested for diabetes drugs Washington An advisory panel for the Food and Drug Administration is urging tougher testing of diabetes drugs for heart risks.

Speaking before a U.S. advisory panel, Cleveland Clinic cardiologist Steven Nissen said higher standards of testing should be enforced to ensure that new proposed diabetes medicines do not damage patients' ...

Drug makers should do more testing to see if proposed new diabetes medicines may damage patients' hearts, a prominent cardiologist told a U.S. advisory panel on Tuesday.

Last summer marked yet another confusing collision between research and practice when the drug name Avandia splashed across front pages all over the country.

We are worried about the recent negative news surrounding GlaxoSmithKline Plc's second largest selling drug, Avandia for diabetes, as well as generic competition to several other products.

The metabolic deregulation associated with diabetes mellitus causes secondary pathophysiologic changes in multiple organ systems.

These articles cover a wide range of subjects, from the most basic aspects of diabetes care to the nitty-gritty specifics.

According to a new research conducted by Jules Stein Eye Institute at the University of California, Los Angeles, use of Rosiglitazone reduces 59.5 % risk of retina damage for diabetes type 2 patients.

Patients with diabetes who take the oral insulin-sensitizing drugs rosiglitazone and pioglitazone may be at an increased risk of suffering hip and wrist fractures.

Editor's Choice Main Category: Eye Health / Blindness Also Included In: Diabetes Article Date: 11 Jun 2008 - 0:00 PDT The diabetes medication rosiglitazone has been associated with a reduction in the likelihood ...

A nearly 7-year study of the effect of intensive blood sugar control with rosiglitazone on the progression of cardiovascular disease in type 2 diabetes showed a slight reduction in cardiovascular events and no ...

New e-Pedigree legislation highlights the lack of end-to-end visibility to track items down to the consumer level.

The Veterans Affairs Diabetes Trial , through two separate analyses, concluded that based on results from VADT, there is no evidence to suggest that use of AVANDIA increases the risk for CV mortality and ...

The medication rosiglitazone may slow the progression of eye disease in diabetes patients, according to new research from the Jules Stein Eye Institute at the University of California, Los Angeles.

A recent event of hypoglycemia, or extremely low blood sugar, in type 2 diabetics was a major predictor of heart attack, stroke and death, a just-finished study by the Department of Veterans Affairs found.

Lowering blood sugar levels to near normal through intensive treatment may reduce the risk of cardiovascular disease and heart attacks for Type 2 diabetics, but only if treatment is begun relatively soon after ...